Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)

Toby M Maher 1,2, Shervin Assassi, 3 Arata Azuma 4,5, Vincent Cottin, 6 Ana-Maria Hoffmann-Vold, 7 Michael Kreuter, 8 Justin M Oldham, 9 Luca Richeldi 10, Claudia Valenzuela 11, Marlies S Wijsenbeek, 12 Carl Cocks, 13 Christina Schlecker, 14 Florian Voss, 15 Daniel Wachtlin, 15 Fernando J Martinez 16

ABSTRACT
Introduction Progressive pulmonary fibrosis (PPF) includes any diagnosis of progressive fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). However, disease progression appears comparable between PPF and IPF, suggesting a similar underlying pathology relating to pulmonary fibrosis. Following positive results in a phase II study in IPF, this phase III study will investigate the efficacy and safety of BI 1015550 in patients with PPF (FIBRONEER-ILD).

Methods and analysis In this phase III, double-blind, placebo-controlled trial, patients are being randomised 1:1:1 to receive BI 1015550 (9 mg or 18 mg) or placebo twice daily over at least 52 weeks, stratified by background nintedanib use. Patients must be diagnosed with pulmonary fibrosis other than IPF that is progressive, based on predefined criteria. Patients must have forced vital capacity (FVC) ≥45% predicted and haemoglobin-corrected diffusing capacity of the lung for carbon monoxide ≥25% predicted. Patients must be receiving nintedanib for at least 12 weeks, or not receiving nintedanib for at least 8 weeks, prior to screening. Patients on stable treatment with permitted immunosuppressives (eg, methotrexate, azathioprine) may continue their treatment throughout the trial. Patients with clinically significant airway obstruction or other pulmonary abnormalities, and those using immunosuppressives that may confound FVC results (cyclophosphamide, tocilizumab, mycophenolate, rituximab) or high-dose steroids will be excluded. The primary endpoint is absolute change from baseline in FVC (mL) at week 52. The key secondary endpoint is the first occurrence of acute ILD exacerbation, hospitalisation for respiratory cause or death, over the duration of the trial.

Ethics and dissemination The trial is being carried out in accordance with the ethical principles of the Declaration of Helsinki, the International Council on Harmonisation Guideline for Good Clinical Practice and other local ethics committees. The study results will be disseminated at scientific congresses and in peer-reviewed publications.

WHAT IS ALREADY KNOWN ON THIS TOPIC
⇒ Treatment with BI 101550 in a phase II study in idiopathic pulmonary fibrosis (IPF) preserved lung function and had an acceptable safety profile. Patients with progressive pulmonary fibrosis (PPF) experience comparable disease progression, lung function decline and mortality as patients with IPF; and therefore it is hypothesised that they share underlying pathobiology and may respond to the same treatments.

WHAT THIS STUDY ADDS
⇒ The phase II trial of BI 101550 was conducted in patients with IPF, and no data exist for patients with PPF. This article describes the study design of FIBRONEER-ILD, a phase III double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with PPF, either alone or with background nintedanib treatment.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY
⇒ This study will explore whether preferential inhibition of the phosphodiesterase 4B subtype, alone or in combination with background nintedanib, is an effective strategy for the treatment of PPF.

Trial registration number NCT05321082.

INTRODUCTION
The term interstitial lung disease (ILD) incorporates over 200 separate disorders characterised by inflammation and/or fibrosis of the lung parenchyma. 1-4 Patients with certain ILD diagnoses other than idiopathic pulmonary fibrosis (IPF)—for example, fibrotic connective tissue disease-associated ILD, fibrotic hypersensitivity pneumonitis, idiopathic non-specific interstitial pneumonia...
and unclassifiable ILD—may develop a progressive phenotype. This progressive phenotype is described by the official American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thorax Association clinical practice guidelines as progressive pulmonary fibrosis (PPF). The disease progression, response to therapy and mortality of these patients are comparable to that observed in patients with IPF. These similarities have led to the hypothesis that IPF and PPF may share common pathogenic mechanisms, and therefore may respond to the same treatments.

Nintedanib is the only antifibrotic therapy approved for the treatment of PPF. Nintedanib, a tyrosine kinase inhibitor first approved for the treatment of IPF based on the INPULSIS trials, was subsequently approved for use in PPF based on the INBUILD trial and for use in systemic sclerosis-associated ILD based on the SENSICIS trial. Although nintedanib treatment can slow disease progression, it does not stop it. Therefore, there is an urgent need for novel treatments that can be used alone or with nintedanib for the treatment of PPF.

BI 1015550 is an oral phosphodiesterase 4 (PDE4) inhibitor that preferentially inhibits the PDE4B subtype. PDE4 inhibitors produce anti-inflammatory effects by reducing the release of proinflammatory mediators and the recruitment of inflammatory cells. The inhibition of PDE4 is also associated with attenuated fibrotic remodelling. Preclinical studies have shown that BI 1015550 has anti-inflammatory and antifibrotic effects in vitro and in vivo models of lung fibrosis, and demonstrated potential synergistic effects with nintedanib on fibroblast proliferation.

PDE4 inhibitors have been associated with gastrointestinal side effects that limit their use, including nausea, emesis and diarrhea. There is evidence that these adverse events are linked to the inhibition of the PDE4D subtype; preferential inhibition of the PDE4B subtype is expected to cause fewer side effects. BI 1015550 is roughly 10-fold more selective for the inhibition of PDE4B versus PDE4D.

The efficacy and safety of treatment with BI 1015550 were investigated in a phase II study in patients with IPF. Overall, BI 1015550 had an acceptable safety profile, with gastrointestinal disorders being reported most frequently and leading to discontinuation in 3.4% of patients. Treatment with BI 1015550 18 mg two times per day (BID) prevented a decline in forced vital capacity (FVC) over 12 weeks. Following these encouraging results, it is anticipated that BI 1015550 may also be effective in patients with PPF, as was seen for nintedanib.

This manuscript describes the study design of FIBRONEER-ILD, a phase III, double-blind, randomised, placebo-controlled trial investigating the efficacy and safety of BI 1015550 in adult patients with PPF, with or without background nintedanib treatment. Patients will be randomly assigned in a 1:1:1 ratio to receive BI 1015550 9 mg or 18 mg BID, or placebo. A sister phase III trial, FIBRONEER-IPF, is being conducted in patients with IPF (NCT05321069) and will be described separately.

METHODS AND ANALYSIS
Trial design and interventions

The FIBRONEER-ILD trial is a phase III, double-blind, randomised, placebo-controlled trial (EudraCT: 1305-0023; ClinicalTrials.gov: NCT05321082) that is being conducted at over 400 sites in up to 45 countries across North, South and Central America, Europe, Africa, Australia and Asia (online supplemental figure 1). The trial began in October 2022 and is estimated to complete in November 2024. It is planned that 1041 patients will be randomised in a 1:1:1 ratio to BI 1015550 9 mg or 18 mg, or placebo BID for at least 52 weeks (figure 1). Patients will be enrolled at both urban and rural centres, ILD academic and expert centres, as well as community pulmonary centres. The 9 mg dose is included to evaluate the benefit-risk profile of BI 101550 at a lower dose, as well as to provide further dose-response and exposure-response data.

The trial consists of two parts. Part A consists of visits 2–10 over a 52-week treatment period. Following completion of the first 52 weeks, patients will remain in the study and continue blinded treatment in part B, over a variable period from visit 10 to the end of the trial, defined as the timepoint when the last patient randomised is expected to reach 52 weeks of treatment (ie, including data beyond 52 weeks). A follow-up visit will be performed 7 days after the end of treatment. Patients who discontinue early from their treatment will be asked to continue study visits. Temporary treatment interruption of BI 1015550 can be considered to manage adverse events. Dose reductions and treatment interruption for background nintedanib are allowed to manage adverse events as per prescribing information.

Randomisation will be performed by BI, the sponsor of the study, with the use of an interactive voice-response system, and the randomisation list will be generated using a validated system, involving a pseudorandom number generator. Randomisation will be stratified by high-resolution CT (HRCT) imaging pattern (usual interstitial pneumonia-like vs other fibrotic patterns), similar to the INBUILD trial, and presence of background treatment with nintedanib (nintedanib group vs non-nintedanib group). The nintedanib group includes patients who are on stable background therapy with nintedanib for at least 12 weeks and plan to continue this background treatment during the trial, whereas the non-nintedanib group includes patients not on treatment with nintedanib for at least 8 weeks. Patients, investigators, central reviewers and everyone involved in trial conduct will be blinded to the randomised treatment assignments.
Patient population

The main inclusion and exclusion criteria are shown in box 1 and online supplemental table 1. Patients aged ≥18 years with any diagnosis of pulmonary fibrosis other than IPF (physician confirmed) are eligible, provided they meet the definition of progression. Patients can be enrolled into the trial without modification of their current nintedanib treatment; however, the number of patients with or without background nintedanib treatment will be monitored to ensure accurate representation of both groups. The definition of progressive ILD is based on the criteria used in the INBUILD trial. Certain immunosuppressive agents (other than corticosteroids) will be permitted in the case of underlying systemic disease (eg, methotrexate, azathioprine), but these must be at a stable dose for at least 12 weeks prior to visit 1 and during the screening period. Similar to the INBUILD trial, certain immunosuppressive agents (cyclophosphamide, tocilizumab, mycophenolate and rituximab) and high-dose steroids (prednisone >15 mg/day or equivalent; online supplemental table 1) will not be allowed in this study. Although these agents are commonly used in real-world practice, they are not approved for the treatment of ILD in most countries and their benefit–risk profiles are not well established. There is evidence that these agents may slow or prevent decline in FVC in some patients with connective tissue disease-related ILDs. Thus, they may confound the assessment of the efficacy and safety of BI 1015550 in patients with PPF.

Outcomes

The primary endpoint is absolute change from baseline in FVC (mL) at week 52. Other endpoints are shown in box 2.

Patient-reported outcome measures will include the Living with Pulmonary Fibrosis Symptoms and Impact questionnaire total scores, EuroQol 5-Dimensional Quality of Life questionnaire total scores and the Patient’s Global Impression of Severity for Cough, Shortness of Breath and Fatigue. Pharmacokinetic endpoints include predose plasma concentrations of BI 1015550. Exploratory biomarkers of inflammation, epithelial injury, tissue degradation and fibrosis will be assessed in blood over time (online supplemental table 3).

Safety

Adverse events will be coded using the Medical Dictionary for Drug Regulatory Activities. An independent data monitoring committee (DMC) that is unblinded to the treatment allocation will monitor the safety and progress of the trial. Safety monitoring and analyses will include physical examination, vital signs, safety laboratory parameters, ECG, review of adverse events reporting, Columbia-Suicide Severity Rating Scale and Hospital Anxiety and Depression Scale. Adverse events of special interest, which include potential severe drug-induced liver injury, vasculitis, severe infections, new onset of severe depression or new onset of severe anxiety, will be monitored.

Statistical analysis

The primary endpoint of absolute change from baseline in FVC (mL) at week 52 will be estimated using a mixed-effect model for repeated measures analysis. This model will include discrete fixed effects for treatment at each visit, baseline intake of nintedanib therapy at each visit, HRCT pattern at each visit and continuous fixed
Box 1  Main inclusion and exclusion criteria

Inclusion criteria
⇒ ≥18 years old.
⇒ Presence of fibrotic lung disease with disease extent >10% on HRCT performed within 12 months of visit 1 as confirmed by central review.
⇒ Patients with pulmonary fibrosis other than IPF who manifest progression according to at least one of the following predefined criteria within 24 months of visit 1:
  ⇒ Relative decline in FVC% predicted of ≥10%.
  ⇒ Decline in FVC% of ≥5% to <10% with worsening of respiratory symptoms.
  ⇒ Decline in FVC% predicted of ≥5% to <10% with increasing extent of fibrotic changes on chest imaging.
  ⇒ Worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging.
⇒ FVC ≥45% of predicted.
⇒ DLco ≥25% of predicted normal corrected for haemoglobin.
⇒ Patients are either on stable treatment* with nintedanib therapy for at least 12 weeks and plan to stay on this background treatment after randomisation, or not on treatment with nintedanib for at least 8 weeks (eg, either antifibrotic treatment naïve or previously discontinued) and do not plan to start or restart antifibrotic treatment.
⇒ Patients treated with permitted immunosuppressive agents (other than corticosteroids) for an underlying systemic disease (eg, methotrexate, azathioprine) need to be on a stable treatment for at least 12 weeks prior to visit 1 and during the screening period.

Exclusion criteria
⇒ Patients treated with the following medications prior to visit 1:
  ⇒ Oral corticosteroids >15 mg/day within 4 weeks.
  ⇒ Cyclophosphamide, tocilizumab or mycophenolate within 8 weeks.
  ⇒ Rituximab within 6 months.
  ⇒ Prebronchodilator FEV1/FVC <0.7 at visit 1.
⇒ Patients with an acute ILD exacerbation within 3 months and/or during the screening period.
⇒ Active, unstable or uncontrolled vasculitis within 8 weeks.
⇒ Any suicidal behaviour (past 2 years) or suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (past 3 months).
⇒ DLco ≥25% of predicted normal corrected for haemoglobin.
⇒ Patients treated with permitted immunosuppressive agents (other than corticosteroids) for an underlying systemic disease (eg, methotrexate, azathioprine) need to be on a stable treatment for at least 12 weeks prior to visit 1 and during the screening period.

*Stable therapy is defined as a tolerated regimen of nintedanib (no dose change) for at least 12 weeks.

Box 2  Endpoints

Primary endpoint
⇒ Absolute change from baseline in FVC (mL) at week 52.

Key secondary endpoint
⇒ Time to first acute ILD exacerbation, first respiratory hospitalisation or death (whichever occurs first) over the duration of the trial.

Other secondary endpoints
⇒ Time to first acute ILD exacerbation or death over the duration of the trial.
⇒ Time to hospitalisation for respiratory cause or death over the duration of the trial.
⇒ Time to absolute decline in FVC% predicted of >10% from baseline or death over the duration of the trial.
⇒ Time to absolute decline in DLco% predicted of >15% from baseline or death over the duration of the trial.
⇒ Time to death over the duration of the trial.
⇒ Absolute change from baseline in L-PF Symptoms dyspnoea domain score at week 52.
⇒ Absolute change from baseline in L-PF Symptoms cough domain score at week 52.
⇒ Absolute change from baseline in L-PF Symptoms fatigue domain score at week 52.
⇒ Absolute change from baseline in FVC% predicted at week 52.
⇒ Absolute change from baseline in DLco% predicted at week 52.

DLco, diffusing capacity of the lung for carbon monoxide; FVC, forced vital capacity; ILD, interstitial lung disease; L-PF, living with pulmonary fibrosis.

The trial plans to randomise 1041 patients so that 347 patients are included in each study arm. Approximately 30% of patients are expected to be on background nintedanib treatment. This corresponds to the current treatment/prescription practices across the participating countries. This sample size will provide approximately 90% power to detect a treatment effect of 71 mL in change from baseline in FVC at week 52 for at least one dose group with an overall type I error of 0.05. For the primary endpoint, statistical significance will be declared if the analyses in either dose group are statistically significant at the designated alpha level according to online supplemental figure 2. The assumed treatment effect of 71 mL was derived based on the assumed FVC decline at week 52 in the placebo arm taking into account the expected number of patients with background nintedanib use, different HRCT patterns (usual interstitial pneumonia-like vs other fibrotic patterns) and FVC changes observed in INPULSIS and INBUILD.

Intercurrent events (except for death and lung transplant) will be handled via a treatment policy strategy. Missing data will not be imputed except for death, where a poor outcome will be assigned. Lung transplant will be handled via a hypothetical strategy. Data measured after a patient’s lung transplantation will be censored. The mixed-effect model will handle missing data based on a likelihood method under the ‘missing at random assumption’. A tipping point analysis is planned as sensitivity analysis to assess the robustness of the primary analysis against deviations from the missing at random effects for baseline FVC (mL) value at each visit. The key secondary endpoint will be analysed using a Cox proportional hazards model with data from the whole trial (ie, including data beyond 52 weeks). The model will include treatment, HRCT pattern, background nintedanib treatment, age, FVC% predicted and diffusing capacity of the lung for carbon monoxide % predicted (corrected for haemoglobin) at baseline as covariates. To account for multiplicity introduced by testing two doses of BI 1015550 vs placebo for the primary and key secondary endpoints, the graphical testing procedure as depicted in online supplemental figure 2 will be used to maintain the family-wise type I error rate at a two-sided alpha level of 0.05.
assumption. The effect of missing data on the primary endpoint will be further investigated using other multiple imputation techniques. Sensitivity analyses, including different covariates in the primary analysis model, will also be performed. Appropriate sample and data management system for clinical data and samples is in place, and patient identification numbers will be used to ensure confidentiality. The investigator or institution will allow site trial-related monitoring, audits, institutional review boards/independent ethics committees review and regulatory inspections.

**Trial governance and oversight**

An independent DMC that is unblinded to the treatment allocation will primarily evaluate safety data and limited efficacy data on a regular basis. An interim analysis to assess the futility of the 9mg BID dose will be performed by the independent DMC when approximately 300 patients in the trial (100 patients per arm) have completed 12 weeks of treatment. The independent DMC will make a recommendation to the sponsor on the continuation or stoppage of the 9mg BID dose arm. The same independent DMC will review the sister trial in IPF (FIBRONEER-IPF) to ensure the broadest possible evaluation of safety in the programme. An independent adjudication committee composed of cardiologists and neurologists will review all fatal cases for the primary cause of death and all adverse events categorised as major adverse cardiovascular events. A separate independent adjudication committee composed of rheumatologists/vasculitis experts will review all events of suspected or possible vasculitis. A contingency plan has been developed for this trial in case patients are not able to perform an on-site visit due to their health status or COVID-19, which includes the direct shipment of investigational products to patients, remote check-ups and home spirometry.

**Patients and public involvement**

During the planning of the FIBRONEER trials, feedback on the trial designs was obtained from a trial simulation involving patients, caregivers and healthcare professionals and during advisory board meetings with members of patient organisations and ILD experts. Participants provided their insights on the trial design, trial assessments, trial visit schedule and duration, and participant support. Patient-focused adaptations were then made to the trial protocols and conduct.

**Ethics and dissemination**

The trial is being conducted in compliance with the ethical principles of the Declaration of Helsinki, in accordance with the International Council on Harmonisation Guideline for Good Clinical Practice, the EU directive 2001/20/EC and the Japanese Good Clinical Practice regulations (Ministry of Health and Welfare Ordinance No. 28, 27 March 1997). Written informed consent will be obtained from each patient before entry into the study. Collection of blood samples for DNA banking is optional and not a prerequisite for participation (only for patients who have signed a separate informed consent form). Samples may be analysed retrospectively. The study results will be disseminated at scientific congresses and in peer-reviewed publications.

**DISCUSSION**

The FIBRONEER-ILD trial is evaluating the efficacy, safety and tolerability of BI 1015550 compared with placebo in patients with PPF in addition to patient’s standard of care over at least 52 weeks. A sister phase III study, FIBRONEER-IPF, is being conducted in parallel in patients with IPF. Together, these studies aim to address the need for new treatments for pulmonary fibrosis.

**Selection of patients with PPF**

The phase II trial of BI 1015550 was conducted in patients with IPF, and no data exist for patients with PPF. However, in patients with PPF, the natural history appears to follow a course similar to IPF, with worsening of respiratory symptoms, lung function decline, reduced quality of life and early mortality. Nintedanib is approved for both IPF and PPF based on similar clinical outcomes and consistent effects in both diseases. Together, this suggests shared underlying pathobiological mechanisms in patients with IPF and PPF. Given the positive efficacy and tolerability results in the phase II trial in IPF, it is hypothesised that similar treatment effects may be seen in patients with PPF.

Furthermore, due to the rare nature of many ILD diagnoses, the grouping of patients with different ILDs that demonstrate PPF behaviour provides an opportunity to conduct an appropriately powered clinical study that is reflective of a real-world population. This grouping is similar to that used in the INBUILD trial, and is justified based on their clinical and biological similarities.

**Targeting inflammation and fibrosis**

ILDs incorporate a wide range of lung disorders, characterised by parenchymal damage mediated by inflammation and fibrosis. PDE4 inhibition is being used in inflammatory diseases such as chronic obstructive pulmonary disease and psoriasis. Many lung diseases that manifest PPF also have an inflammatory component, including fibrotic connective tissue disease-associated ILD, fibrotic hypersensitivity pneumonitis and idiopathic non-specific interstitial pneumonia. PDE4 inhibition produces anti-inflammatory effects by reducing the release of proinflammatory mediators and reducing the recruitment of inflammatory cells. Preclinical evidence has also shown that PDE4 inhibitors are associated with antifibrotic effects and may reduce fibrotic remodelling in lung disease. In preclinical studies, BI 1015550 has...
demonstrated anti-inflammatory and antifibrotic effects in in vitro and in vivo models of lung fibrosis.16

Rationale for including patients with and without background nintedanib
In preclinical studies, the combination of nintedanib and BI 1015550 demonstrated potentially synergistic effects on the inhibition of fibroblast proliferation in primary lung fibroblasts in patients with IPF.16 In the phase II trial, treatment with BI 1015550 at 18 mg BID preserved lung function in patients with IPF over the 12-week study period in patients either receiving or not receiving antifibrotic therapy,18 with suggestion of an additive effect with nintedanib.20

Predose and postdose concentration levels of BI 1015550 were similar between patients treated with nintedanib and those not treated with any antifibrotics, indicating that nintedanib use did not impact the exposure of BI 1015550.20 Thus, the efficacy and safety of BI 1015550 will be assessed in patients with PPF with or without background nintedanib treatment.

Rationale for dose selection
The selection of the BI 1015550 18 mg BID dose is supported by the results from the phase II study, where BI 1015550 treatment preserved lung function in patients with IPF.18 In this phase III trial, we have an additional 9 mg BID dose to evaluate the benefit-risk profile at a lower dose, as well as to provide further dose-response and exposure-response data. An interim futility analysis is planned to assess the efficacy and safety profile of the 9 mg BID dose, ensuring patients are exposed to the lower dose for the shortest period possible in case of a non-favourable benefit-risk profile.

Rationale for the choice of inclusion and exclusion criteria
This study opted for similar criteria to the INBUILD trial, given its successful use in a large sample of patients with fibrosing lung disease.7 The study protocol was developed prior to the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thorax Association 2022 guidelines on definition of PPF.9 Although there are minor differences between this definition and the INBUILD criteria, the inclusion criteria used in this trial are inclusive of a broad population of patients with PPF. There is no upper limit for age or FVC, and patients will be included if they have FVC% predicted of ≥45%, which may be more representative of patients with PPF in the real world. Certain immunosuppressive agents that may impact FVC (eg, cyclophosphamide, tocilizumab, mycophenolate, rituximab) will not be allowed in this study, to avoid the potential confounding impact of these drugs on the assessment of the efficacy and safety of BI 1015550 in PPF.

Rationale for trial endpoints
The study endpoints are consistent with previous trials and reflect clinically meaningful outcomes. In this study, the primary endpoint is absolute change from baseline in FVC (mL) at week 52. This differs from the primary endpoint of annual rate of decline in FVC (mL/year) used in the INBUILD trial due to findings from the phase II study of BI 1015550 in patients with IPF; the phase II study showed an early increase in FVC in the treated group, suggesting a non-linear course. In contrast, a continuous decline was observed with nintedanib in INBUILD.18 Thus, change from baseline FVC (mL) may be a more suitable endpoint for this phase III study.

The short duration of the phase II study and its small sample size limit the conclusions that can be drawn regarding the treatment effect of 18 mg BID.18 In this phase III trial, the minimum treatment period of 52 weeks has been selected according to the guidance from American and European clinician organisations (2015 American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thorax Association guidelines) to confirm these treatment effects on FVC over a longer time period and in a larger sample of patients.30 This study also includes a variable period in which patients will continue treatment with BI 1015550 or placebo beyond week 52. Patients with PPF may have different underlying pathophysiology to those with IPF. Thus, there may be heterogeneity in rates of progression and response to treatment throughout the trial. This time scale will also allow more time and longer follow-up, to record more events for the assessment of the key secondary endpoint (time to first exacerbation, hospitalisation due to respiratory cause or death), thus increasing the power of the trial. In addition, specific efficacy and safety endpoints and changes in clinically significant outcomes may vary in occurrence and may only become apparent beyond 52 weeks.

Safety assessments
Depression and suicidal ideation or behaviour are listed as side effects associated with marketed oral pan-PDE4 inhibitors, and therefore, will be monitored as part of the safety assessments in this trial.31–35 In preclinical toxicology studies, PDE4 inhibitors have been associated with vasculitis.36–39 In the phase II study, there was one patient with suspected vasculitis and IPF exacerbation, but vasculitis was not confirmed by the independent DMC.18 Patients will be monitored for vasculitis during this trial and suspected cases will be assessed by the independent adjudication committee and independent DMC.

Limitations
While some immunosuppressive agents (eg, methotrexate, azathioprine) will be permitted, cyclophosphamide, tocilizumab, mycophenolate, rituximab and high-dose steroids will not be allowed in this study, to avoid...
the potential confounding impact of these drugs on the assessment of the efficacy and safety of BI 1015550 in PPF. This is a limitation of the trial, as many patients with PPF may use these immunosuppressive agents and biologics in real-world practice.

CONCLUSIONS

The FIBRONEER-ILD trial is investigating the efficacy, safety and tolerability of oral BI 1015550 in patients with PPF, over a long-term period, in patients with or without nintedanib. The study commenced in October 2022. Following the positive results of the BI 1015550 phase II trial in patients with IPF and the similarities in disease course between IPF and PPF, it is anticipated that treatment effects may also be seen in patients with PPF.

Author affiliations

1Department of Pulmonary, Critical Care and Sleep Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA
2Section of Inflammation, Repair and Development, Imperial College London National Heart and Lung Institute, London, UK
3Division of Rheumatology, University of Texas McGovern Medical School, Houston, Texas, USA
4Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan
5Respiratory Medicine and Clinical Research Centre, Meisei Hospital, Saitama, Japan
6Service de pneumologie, Hôpital Louis Pradel, Centre de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, INRAE, member of ERN-LUNG, Lyon, France
7Department of Rheumatology, Oslo University Hospital, Oslo, Norway
8Center for Interstitial and Rare Lung Diseases, Department of Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany
9Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA
10Unita Operativa Complessa di Pneumologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
11ILD Unit, Pulmonology Department, Hospital University de la Princesa, University Autonoma de Madrid, Madrid, Spain
12Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
13Boehringer Ingelheim SComm, Brussels, Belgium
14Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
15Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
16Department of Medicine, Cornell University, New York City, New York, USA

Author note: This work was supported by Boehringer Ingelheim International. The corresponding author had full access to the study data and had final responsibility for the decision to submit for publication.

Acknowledgements: The authors report conflicts of interest as per the disclosure and conflict of interest forms. The authors report no other conflicts of interest. The authors report conflicts of interest as per the disclosure and conflict of interest forms. The authors report no other conflicts of interest.

Funding: This study was funded by Boehringer Ingelheim International.

Competing interests: TM has received consulting fees from Boehringer Ingelheim, Roche/Genentech, AstraZeneca, Bayer, Biogen, Celgene, CSL Behring, Ferring, Galapagos, Janssen, Merck, Novartis, AbbVie, Bristol Myers Squibb, Genentech, Gilead, GSK, IQVIA, Janssen, Medscape, Merck, Novartis, Roche, Sanofi, and Vertex. RA has received research grants and speaker fees from Boehringer Ingelheim and Takeda Pharma, and been an advisory committee member for Boehringer Ingelheim, Takeda Pharma, and Takeda Medical Co. and Kyorin Pharma. VC has received unrestricted grants from Boehringer Ingelheim; consulting fees from AstraZeneca, Boehringer Ingelheim, Celgene/BMS, CSL Behring, Ferring, Galapagos, Pliant, PureTech, RedX, Roche, Sanofi and Shionogi; lecture fees from Boehringer Ingelheim and Roche; support for attending meetings from Boehringer Ingelheim and Hoffmann-La Roche; has participated in data and safety monitoring boards for Galapagos, Galacto and Roche; and been on an adjudication committee for Fibrogen. AA has received research grants from Boehringer Ingelheim and the Italian Medicine Agency; been an advisory board member for Roche, Boehringer Ingelheim, Fibrogen and Promedon; been involved in consulting activity for Biogen, Celgene, Genentech, Nitto, Pliant Therapeutics, Toray, Bristol Myers Squibb, Respirovant and CSL Behring; received payment for lectures from Boehringer Ingelheim, Zambon and Cipla; received support for attending meetings from Boehringer Ingelheim, Galapagos, and Roche; and been a steering committee member for Boehringer Ingelheim and Roche. CV has received personal fees from Boehringer Ingelheim, Roche and Bristol Myers Squibb; and support for attending meetings from Boehringer Ingelheim and Roche. MSW has received grants from AstraZeneca-Daiichi, Boehringer Ingelheim, Hoffmann-La Roche, The Netherlands Organisation for Health Research and Development, The Dutch Lung Foundation and The Dutch Pulmonary Society; consulting fees from Boehringer Ingelheim, Galapagos, Bristol Myers Squibb, Galacto, Respirovant and Nelfinavir Therapeutics, Horizon Therapeutics, PureTech Health, Kinevant Sciences, Molecule, CSL Behring, Thyrion and Vicroc; speaker fees from Boehringer Ingelheim, Galapagos, Hoffmann-La Roche, Novartis and CSL Behring; support for attending meetings from Boehringer Ingelheim, Galapagos and Hoffmann-La Roche; has participated in advisory boards for Savara, Galapagos and Dutch lung fibrosis and sarcoidosis patient associations (unpaid); and has held leadership roles as chair of the Idiopathic Interstitial Pneumonia group of the European Respiratory Society, member of the board of the Netherlands Respiratory Society, member of the scientific advisory board of the European Idiopathic Pulmonary Fibrosis and Related Disorders Federation and chair of the educational committee of the European Reference Network for Rare Lung Diseases. All grants and fees were paid to her institution. CC, CS, FV and DW are employees of Boehringer Ingelheim. FJM has served on a steering committee, advisory board, data safety monitoring board or adjudication committee for Affero/Mercck, Bayer, Boehringer Ingelheim, Galapagos, Nitto, Respirovant, Roche and Veracyce. AA has received research grants from Boehringer Ingelheim, Galapagos, Bristol Myers Squibb, Bridge Biotherapeutics, CSL Behring, DevPro, IQVIA, Roche/Genentech, Sanofi, Shionogi, twoXAR, United Therapeutics and Veracyce.

Patient and public involvement: Patients and/or the public were involved in the design, conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication: Not applicable.

Provenance and peer review: Not commissioned; externally peer reviewed.

Data availability statement: To ensure independent interpretation of clinical study results and enable authors to fulfill their role and obligations under the ICMJE criteria, Boehringer Ingelheim grants all external authors access to clinical study data pertinent to the development of the publication. In adherence with the Boehringer Ingelheim Policy on Transparency and Publication of Clinical Study Data, scientific and medical researchers can request access to clinical study data when it becomes available on the https://widl.org/ link, and earliest after publication of the primary manuscript in a peer-reviewed journal, regulatory activities are complete, and other criteria are met. Please visit https://www.mystudystwindow.com/msw/datasharing for further information.

Author note: IPD sharing statement: Sharing of individual clinical trial participant-level data (IPD) is not planned.
Supplemental material  This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access  This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs  Toby M Maher http://orcid.org/0000-0001-7192-9149
Arata Azuma http://orcid.org/0000-0003-0506-9966
Luca Richeldi http://orcid.org/0000-0001-8594-1448
Claudia Valenzuela http://orcid.org/0000-0002-0856-6290

29 Boehringer Ingelheim International GmbH. A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 105550 taken orally; 2019.
### Inclusion criteria
- Women of childbearing potential must agree to use highly effective methods of birth control. Women of childbearing potential taking oral contraceptives also have to use one barrier method
- Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial

### Exclusion criteria
- Other clinically significant pulmonary abnormalities, in the opinion of the investigator
- Relevant chronic or acute infections, including human immunodeficiency virus and viral hepatitis
- Patients having developed ILD due to SARS-CoV-2 infection/COVID-19 within 12 months of screening (based on investigator judgement)
- Major surgery (according to the investigator’s assessment) performed within 6 weeks prior to randomisation or planned during the trial period, e.g. hip replacement (registration on lung transplantation list would not be considered as planned major surgery)
- Any documented active or suspected malignancy or history of malignancy within 5 years prior to visit 1, except appropriately treated basal cell carcinoma of the skin, in situ squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix
- AST or ALT >2.5 x ULN or total Bilirubin >1.5 x ULN at visit 1
- eGFR ≤30 mL/min/1.73 m² at visit 1 (Chronic Kidney Disease Epidemiology)
- Patients with underlying liver cirrhosis (Child–Pugh A, B or C hepatic impairment)
- Cardiovascular diseases (severe hypertension, defined by uncontrolled/under treatment ≥160/100 mm Hg, on multiple occasions within 3 months of visit 1; myocardial infarction, stroke or transient ischaemic attack within 6 months of visit 1; unstable cardiac angina within 6 months of visit 1)
- Patients treated with prednisone >15 mg/day or equivalent within 4 weeks of visit 1; cyclophosphamide, tocilizumab, mycophenolate within 8 weeks of visit 1; rituximab within 6 months of visit 1
- Any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale in the past 3 months or at visit 1 and/or visit 2 (i.e. active suicidal thought with method and intent but without specific plan; or active suicidal thought with method, intent and plan)
- Acute or chronic severe depression defined as HADS subscore >14 at visit 1 and/or visit 2
- Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
- Patients treated with PDE1, PDE3, PDE4, PDE10 inhibitors and non-selective PDE inhibitors within 30 days before visit 1
- Patients not expected to comply with the protocol requirements or not expected to complete the trial as scheduled (e.g. chronic alcohol or drug abuse, or any other condition that, in the investigator's opinion, makes the patient an unreliable trial participant)
- Inability to refrain from smoking on trial visit days
- History of allergy, hypersensitivity or contraindications to the class of drugs under study, including known hypersensitivity to the drug or its excipients
- Patients with a significant disease or condition other than the ILD under study, which, in the opinion of the investigator, may put the patient at risk because of
participation, interfere with study procedures, or cause concern regarding the patient’s ability to participate in the study

- Patients with active tuberculosis
- Previous randomisation in this trial or in the FIBRONEER-IPF trial
- Currently enrolled in another investigational device or drug trial, or less than 30 days since ending another investigational device or drug trial(s) or receiving other investigational treatment(s)
- Women who are pregnant, nursing or who plan to become pregnant while in the trial
- History of stem cell therapy for the treatment of pulmonary fibrosis

AST, aspartate aminotransferase; ALT, alanine transaminase; COVID-19, coronavirus disease 2019; eGFR, estimated glomerular filtration rate; HADS, Hospital Anxiety and Depression Scale; ICH-GCP, International Conference on Harmonisation-Good Clinical Practice; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; PDE, phosphodiesterase; SARS-CoV-2, severe acute respiratory syndrome coronavirus; ULN, upper limit of normal.
## Supplementary Table 2. Equivalent doses of corticosteroids

<table>
<thead>
<tr>
<th>Drug</th>
<th>Equivalent dose (mg)</th>
<th>Conversion factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisone</td>
<td>5</td>
<td>x 1</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>5</td>
<td>x 1</td>
</tr>
<tr>
<td>Triamcinolone</td>
<td>4</td>
<td>x 1.25</td>
</tr>
<tr>
<td>6-Methylprednisolone</td>
<td>4</td>
<td>x 1.25</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>1</td>
<td>x 5</td>
</tr>
<tr>
<td>Betamethasone</td>
<td>0.75</td>
<td>x 6.7</td>
</tr>
<tr>
<td>16-Methylprednisolone</td>
<td>6</td>
<td>x 0.8</td>
</tr>
<tr>
<td>Fluocortolone</td>
<td>5</td>
<td>x 1</td>
</tr>
<tr>
<td>Cloprednol</td>
<td>3.75-5</td>
<td>x 1.0-1.5</td>
</tr>
<tr>
<td>Deflazacort</td>
<td>6</td>
<td>x 0.8</td>
</tr>
<tr>
<td>Cortisol (hydrocortisone)</td>
<td>20</td>
<td>x 0.25</td>
</tr>
<tr>
<td>Cortisone</td>
<td>25</td>
<td>x 0.20</td>
</tr>
</tbody>
</table>
Supplementary Table 3. Further endpoints and exploratory biomarkers

<table>
<thead>
<tr>
<th>Further endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Time to first acute ILD exacerbation over the duration of the trial</td>
</tr>
<tr>
<td>• Time to absolute decline from baseline in FVC (% predicted) &gt;10% from baseline over the duration of the trial</td>
</tr>
<tr>
<td>• Time to hospitalisation for respiratory cause over the duration of the trial</td>
</tr>
<tr>
<td>• Annual rate of decline in FVC (mL/year) as measured over 52 weeks</td>
</tr>
<tr>
<td>• Absolute change from baseline in FVC% predicted at week 26</td>
</tr>
<tr>
<td>• Absolute change from baseline in FVC (mL) at week 26</td>
</tr>
<tr>
<td>• Absolute change from baseline in DLco% predicted at week 26</td>
</tr>
<tr>
<td>• Time to a relative decline from baseline in FVC% predicted of &gt;10% or death over the duration of the trial</td>
</tr>
<tr>
<td>• Time to an absolute decline from baseline in FVC% predicted of &gt;5% or death over the duration of the trial</td>
</tr>
<tr>
<td>• Time to a relative decline from baseline in FVC% predicted of &gt;5% or death over the duration of the trial</td>
</tr>
<tr>
<td>• Absolute change from baseline in L-PF Impact score at week 52</td>
</tr>
<tr>
<td>• Absolute change from baseline in L-PF Symptoms total score at week 52</td>
</tr>
<tr>
<td>• Absolute change from baseline in L-PF total score at week 52</td>
</tr>
<tr>
<td>• Change from baseline in SpO₂ (expressed in percent) at rest at week 52</td>
</tr>
<tr>
<td>• Time to first non-elective hospitalisation for any cause or death over the duration of the trial</td>
</tr>
<tr>
<td>• Time to first use of nintedanib or immunosuppressive (rescue) therapy over the duration of the study (non-nintedanib group)</td>
</tr>
<tr>
<td>• Annualised rate of hospitalisation for respiratory cause</td>
</tr>
</tbody>
</table>
**Exploratory biomarkers**

- Protein biomarkers such as KL-6, SP-D, MMP7, COMP, vWF, CA-125 and CA19-9
- Further protein markers and neoepitopes, including C3M, PRO-C3, C6M, PRO-C6, and unspecified mRNAs and miRNAs

DLco, diffusing capacity of the lung for carbon monoxide; FVC, forced vital capacity; ILD, interstitial lung disease; KL-6, Krebs von den Lungen 6; L-PF, Living with Pulmonary Fibrosis Symptoms and Impact questionnaire; miRNA, micro-RNA; MMP7, metalloproteinase-7; SP-D, surfactant protein D; SpO₂, oxygen saturation; vWF, von Willebrand factor.
Supplementary Figure 1. Countries where patient enrolment will take place

Countries: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Croatia, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Saudi Arabia, Serbia, Singapore, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States.

Supplementary Figure 2. Graphical testing procedure for hypothesis testing strategy

\[ H_{0.1, \alpha} = 0.04 \]
BI 1015550 18 mg BID vs placebo
Absolute change from baseline in FVC (mL) at week 52

\[ H_{0.2, \alpha} = 0.01 \]
BI 1015550 9 mg BID vs placebo
Absolute change from baseline in FVC (mL) at week 52

\[ 0.5 \]

\[ 1 - \epsilon \]

\[ 1 \]

\[ \epsilon \]

\[ H_{0.3, 0} \]
18 mg BID vs placebo
Time to first respiratory hospitalisation or ILD exacerbation or death

\[ H_{0.4, 0} \]
9 mg BID vs placebo
Time to first respiratory hospitalisation or ILD exacerbation or death

\( \epsilon \) is set to a negligible amount of 0.0001 at the start.

BID, twice daily; FVC, forced vital capacity; ILD, interstitial lung disease.